CEL-SCI is dedicated to improving the treatment of cancer and other diseases by unleashing the power of the immune system; the body's natural and most potent defense system.

Our flagship product, Multikine®, is the first immunotherapeutic agent being developed as a first-line standard of care treatment for cancer. Multikine simulates the activities of a healthy person's immune system, and  unleashes and empowers the body's own anti-tumor immune response.

Multikine® has been cleared in the U.S. and Canada for a groundbreaking global Phase III clinical trial in advanced primary (not yet treated) head and neck cancer patients. This trial is expected to be the largest head and neck cancer clinical study ever conducted.

It is also the first Phase III study in the world in which immunotherapy is given to cancer patients first, i.e. prior to their receiving any conventional treatment for cancer, including surgery, radiation and/or chemotherapy.  This is significant because conventional therapy weakens the immune system, and likely compromises the benefits of immunotherapy.  Multikine works by activating the intact immune system because it is given before the ravages of conventional cancer therapy. Read more about our trial

Multikine® is a different kind of weapon in the fight against cancer; Multikine is a defined mixture of cytokines.   It is the first of a new class of cancer immunotherapy called combination immunotherapy, possessing both active and passive properties.

Multikine® is the only immunotherapy that is able to directly kill the tumor cells themselves in a targeted way, as well as activate the patient’s own anti-tumor immune response. Multikine is non-toxic because it works with the body’s immune system.  Multikine will be manufactured in CEL-SCI's state-of-the-art "Cold-Fill" manufacturing facility outside of Baltimore. Read more about Multikine